Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: NASDBULL who wrote (343)	3/31/1999 5:41:00 PM
From: gao seng	Read Replies (1) \| Respond to of 550

SU5416: The Company initiated Phase I clinical testing in September 1997 with its lead angiogenesis inhibitor, SU5416, a Flk-1/KDR TK inhibitor, which is designed to inhibit the growth and spread of cancer by preventing the formation of new blood vessels (angiogenesis) required to nourish the tumor. To date, SU5416 has shown an excellent safety profile in over 100 patients with a range of solid tumors, including advanced colorectal, lung and renal cell cancers, and AIDS-related Kaposi's sarcoma; anecdotal indications of activity have been observed in a number of patients, including prolonged periods of stable disease and some instances of tumor shrinkage. After extensive consultation with numerous oncology opinion leaders, the Company announced plans to accelerate the development of SU5416 with the initiation of Phase III clinical trials in non small cell lung and colorectal cancers, and Phase II/III studies in AIDS-related Kaposi's sarcoma in the U.S. and Europe this year. Meanwhile, the Company will be working with certain investigators on NCI-sponsored Phase II studies in other cancer indications. This strategy may expedite the commercialization of SU5416, which has the potential to become the first specific angiogenesis inhibitor to reach the U.S. market. There can be no assurance that this commercialization strategy will result in accelerated commercialization of SU5416 or that other angiogenesis inhibitors will not receive regulatory approval prior to any approval of SU5416. from 10-K filed today